Johnson & Johnson (China) Investment Ltd. today announced it has acquired Guangzhou Bioseal Biotechnology Co., Ltd. (Bioseal) a privately held biopharmaceutical company specializing in the design, development and commercialization of a porcine plasma-derived biologic product for controlling bleeding during surgery… Financial terms of the transaction are not being disclosed.
Makes sense—as we found out during the heparin crisis a few years ago, China is where the pigs are.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”